Combination Approaches in PD-L1–Positive Metastatic Triple Negative Breast Cancer

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).

 

Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metastatic TNBC, the implications of recent trials like ASCENT-04, and the potential of antibody-drug conjugates (ADCs) such as sacituzumab govitecan and datopotamab deruxtecan.

Key topics included:

• The role of PD-L1 positivity in treatment decisions
• Insights from the ASCENT-04 trial and its findings
• Common side effects associated with sacituzumab and strategies for management
• The future of immunotherapy and ADCs in TNBC treatment

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable information and clinical pearls.

 

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

• ⁠X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/ 

 

Don't forget to subscribe for more insightful discussions on cancer treatment!

#TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers